The past two months turned out to be a nightmare for shareholders of Pain Therapeutics (NASDAQ:PTIE). Shares have fallen nearly 81% after the FDA rejected …
In this article, we walk investors through today’s Pain Therapeutics (NASDAQ:PTIE) bloodbath. Shares are down 70% as an FDA advisory committee voted overwhelmingly …
Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …
Pain Therapeutics, Inc. (NASDAQ:PTIE) is looking at an eventful upcoming stretch concerning Remoxy, its late-stage drug candidate.
Pain Therapeutics, Inc. (NASDAQ:PTIE) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 60% …